

# Nancy K Sweitzer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11531622/publications.pdf>

Version: 2024-02-01

87  
papers

7,911  
citations

81900

39  
h-index

62596

80  
g-index

87  
all docs

87  
docs citations

87  
times ranked

7984  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	27.0	1,993
2	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation</i> , 2015, 131, 34-42.	1.6	758
3	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016, 37, 455-462.	2.2	396
4	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
5	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 180-187.	3.9	319
6	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 104-115.	3.9	288
7	Heart Failure With Recovered Ejection Fraction. <i>Circulation</i> , 2014, 129, 2380-2387.	1.6	244
8	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	3.9	224
9	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	3.9	218
10	Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1165-1172.	2.8	189
11	Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 183-190.	3.9	169
12	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 184-192.	3.9	154
13	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. <i>Circulation: Heart Failure</i> , 2018, 11, e005266.	3.9	143
14	Comparison of Clinical Features and Outcomes of Patients Hospitalized With Heart Failure and Normal Ejection Fraction (≥55%) Versus Those With Mildly Reduced (40% to 55%) and Moderately to Severely Reduced (<40%) Fractions. <i>American Journal of Cardiology</i> , 2008, 101, 1151-1156.	1.6	126
15	Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 228-238.	4.1	123
16	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
17	Does Race Influence Decision Making for Advanced Heart Failure Therapies?. <i>Journal of the American Heart Association</i> , 2019, 8, e013592.	3.7	108
18	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1570-1577.	7.1	106

#	ARTICLE	IF	CITATIONS
19	Neuregulin-1 <sup>2</sup> Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. <i>Circulation</i> , 2009, 120, 310-317.	1.6	103
20	Loss-of-function DNA sequence variant in the <i>CLCNKA</i> chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2456-2461.	7.1	95
21	Association of Gender and Race With Allocation of Advanced Heart Failure Therapies. <i>JAMA Network Open</i> , 2020, 3, e2011044.	5.9	91
22	Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure. <i>Journal of the American Heart Association</i> , 2014, 3, e000550.	3.7	81
23	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 382	1.6	80
24	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	3.9	70
25	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	4.1	68
26	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	4.1	68
27	The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 386-394.	2.8	65
28	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	7.1	65
29	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. <i>Circulation: Heart Failure</i> , 2018, 11, e005008.	3.9	58
30	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	4.1	56
31	Decreased Cardiac Functional Reserve in Heart Failure With Preserved Systolic Function. <i>Journal of Cardiac Failure</i> , 2011, 17, 301-308.	1.7	55
32	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	1.7	53
33	Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 1215-1229.	3.2	49
34	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	1.7	49
35	What Is an Angiotensin Converting Enzyme Inhibitor?. <i>Circulation</i> , 2003, 108, e16-8.	1.6	46
36	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 256-262.	1.7	46

#	ARTICLE	IF	CITATIONS
37	Increases in Central Aortic Impedance Precede Alterations in Arterial Stiffness Measures in Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2886-2891.	8.6	41
38	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1000.	6.1	41
39	Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 368-373.	1.7	40
40	Economic Issues in Heart Failure in the United States. <i>Journal of Cardiac Failure</i> , 2022, 28, 453-466.	1.7	40
41	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 674-693.	1.7	39
42	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	3.9	35
43	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	3.9	31
44	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	7.1	28
45	Biomarker Predictors of Cardiac Hospitalization in Chronic Heart Failure: A Recurrent Event Analysis. <i>Journal of Cardiac Failure</i> , 2014, 20, 569-576.	1.7	26
46	Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. <i>European Journal of Heart Failure</i> , 2013, 15, 560-564.	7.1	25
47	Decreased T-Cell Responses to Influenza Vaccination in Patients with Heart Failure. <i>Pharmacotherapy</i> , 2010, 30, 10-16.	2.6	21
48	Effect of Renal Function on Prognosis in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 62-68.	1.6	21
49	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	3.9	21
50	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin in Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	1.6	21
51	Application of the H <sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	7.1	18
52	Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients. <i>Circulation</i> , 2021, 143, 2412-2414.	1.6	18
53	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008293.	3.9	18
54	Lack of Persistence of Influenza Vaccine Antibody Titers in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 105-109.	1.7	15

#	ARTICLE	IF	CITATIONS
55	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 714-721.	0.6	15
56	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. <i>American Journal of Cardiology</i> , 2016, 118, 1855-1860.	1.6	15
57	Medical Misinformation: Vet the Message!. <i>Journal of the American Heart Association</i> , 2019, 8, e011838.	3.7	15
58	Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?. <i>Circulation: Heart Failure</i> , 2020, 13, e006544.	3.9	14
59	Left Ventricular Responses to Acute Changes in Late Systolic Pressure Augmentation in Older Adults. <i>American Journal of Hypertension</i> , 2013, 26, 866-871.	2.0	10
60	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. <i>American Heart Journal</i> , 2022, 244, 135-148.	2.7	10
61	Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors: UNOS Registry Propensity-Matched Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012894.	3.7	9
62	Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 840-848.	0.6	9
63	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	1.7	8
64	Imbalance in Heart Transplant to Heart Failure Mortality Ratio by Sex. <i>Journal of the American Heart Association</i> , 2021, 10, e020146.	3.7	7
65	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	4.1	6
66	Sex Disparities in Organ Donation: Finding an Equitable Donor Pool. <i>Journal of the American Heart Association</i> , 2021, 10, e020820.	3.7	6
67	More Appropriate Cardiovascular Risk Screening Through Understanding Complex Phenotypes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1438-1440.	2.8	5
68	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	7.1	5
69	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2020, 22, 557-559.	7.1	5
70	Nonmalignant Diagnoses in Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 2638-2639.	1.6	4
71	Determinants of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2547-2548.	2.8	4
72	New Therapeutic Target in Heart Failure. <i>Circulation</i> , 2018, 137, 1331-1333.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development, 2018, 3, 319-329.	0.7	3
74	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	2.2	3
75	Relationships between 2018 UNOS heart policy and transplant outcomes in metropolitan, micropolitan, and rural settings. Journal of Heart and Lung Transplantation, 2022, 41, 1228-1236.	0.6	3
76	When the VEST Does Not Fit. Circulation: Heart Failure, 2018, 11, e005116.	3.9	2
77	Choosing a Career in Heart Failure. Circulation: Heart Failure, 2019, 12, e006139.	3.9	2
78	The association between heart rate behavior and gait performance: The moderating effect of frailty. PLoS ONE, 2022, 17, e0264013.	2.5	2
79	Continuing Medical Education Activity in Echocardiography. Echocardiography, 2013, 30, 512-512.	0.9	1
80	Looking Ahead: Circulation: Heart Failure in 2022. Circulation: Heart Failure, 2022, 15, e009405.	3.9	1
81	Re: Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. Journal of Cardiac Failure, 2009, 15, 549-551.	1.7	0
82	Editor's Perspective. Circulation: Heart Failure, 2017, 10, .	3.9	0
83	Apophenia and the Crafting of a Circulation: Heart Failure Issue. Circulation: Heart Failure, 2018, 11, e005027.	3.9	0
84	Showcasing Heart Failure Science at the American Heart Association Scientific Sessions. Circulation: Heart Failure, 2020, 13, e008157.	3.9	0
85	Science in the Time of Coronavirus. Circulation: Heart Failure, 2020, 13, e007115.	3.9	0
86	Grace Under Pressure. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE122009513.	3.9	0
87	2021: A Look Back. Circulation: Heart Failure, 2021, 14, e009358.	3.9	0